IQSEC2 Inhibitors
Chemical inhibitors of IQSEC2 can be understood by examining their effects on various cellular pathways that are indirectly involved in the functional activity of this protein. NSC 23766, EHop-016, and ZCL278 target the GTPase signaling pathway, which is intricately linked with the actin cytoskeleton dynamics regulated by IQSEC2. NSC 23766 specifically inhibits the Rac1 GTPase by targeting its exchange factors, thereby impacting IQSEC2's role in actin reorganization. Similarly, EHop-016 disrupts Rac1 activation by inhibiting Vav2, a guanine nucleotide exchange factor, which in turn affects the functional activity of IQSEC2. ZCL278's inhibition of Cdc42 GTPase also implicates a reduction in IQSEC2 activity since Cdc42 is part of the cellular processes involving actin cytoskeleton organization, which IQSEC2 is known to influence.
Continuing with the theme of GTPase inhibition, ML141, and SecinH3 add to the arsenal against IQSEC2's activity. ML141 and CID2950007 are both inhibitors of Cdc42, which indirectly reduce IQSEC2 activity by impacting the actin cytoskeleton. SecinH3 inhibits cytohesins, disrupting Arf GTPase activation, and since IQSEC2 acts as a guanine nucleotide exchange factor (GEF) for Arf6, this inhibition translates to reduced activity of IQSEC2. Miuraenamide A and Brefeldin A directly target the Sec7 domain of Arf GEFs, with Miuraenamide A inhibiting this domain in IQSEC2, leading to a direct decrease in its GEF activity for Arf6. Brefeldin A also inhibits the exchange of GDP for GTP on Arf proteins, affecting IQSEC2's ability to activate Arf6. AG-1478, LY294002, and Wortmannin disrupt upstream signaling pathways that are prerequisites for full IQSEC2 functionality. AG-1478 inhibits EGFR, which impacts the activation of small GTPases involved with IQSEC2 pathways. LY294002 and Wortmannin both inhibit PI3K, which is involved in signaling processes that regulate actin cytoskeleton reorganization, a cellular event where IQSEC2's role is critical. Finally, Y-27632, a ROCK inhibitor, alters actin cytoskeleton dynamics and thus has an indirect inhibitory effect on IQSEC2's function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits the Rac1-specific guanine nucleotide exchange factor (GEF) activity, which is crucial for the activation of Rac1, a GTPase that interacts with IQSEC2 for Arf6 activation. By inhibiting Rac1, this chemical indirectly inhibits IQSEC2's function in actin cytoskeleton reorganization. | ||||||
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $80.00 | ||
EHop-016 is a Rac1 GTPase inhibitor that acts by targeting the Vav2 GEF, which is necessary for Rac1 activation. Since IQSEC2 is involved in Arf6 activation via Rac1, inhibition of Rac1 by EHop-016 can indirectly lead to decreased functional activity of IQSEC2. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
ZCL278 is a Cdc42 GTPase inhibitor that targets the Cdc42-Intersectin interaction, impairing the Cdc42-dependent signaling pathway. As IQSEC2 is implicated in actin cytoskeleton dynamics, inhibition of Cdc42 can indirectly impede IQSEC2-mediated signaling events. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a potent, selective, and reversible inhibitor of Cdc42 GTPase. By inhibiting Cdc42, ML141 can indirectly reduce the functional activity of IQSEC2, as Cdc42 is part of the cellular processes involving actin cytoskeleton organization that IQSEC2 is known to influence. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 inhibits cytohesins, which are Arf GTPase exchange factors, leading to a reduction in Arf activation. As IQSEC2 functions as a GEF for Arf6, inhibition of cytohesins by SecinH3 indirectly impacts IQSEC2's capacity to facilitate Arf6 activation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A interferes with the function of Arf GEFs by inhibiting the exchange of GDP for GTP on Arf proteins. As IQSEC2 has GEF activity for Arf6, Brefeldin A's mechanism of action can result in the functional inhibition of IQSEC2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/Akt signaling pathway. IQSEC2 function is associated with actin cytoskeleton reorganization, a process influenced by PI3K/Akt signaling. Inhibition of PI3K can thus indirectly lead to inhibition of IQSEC2-mediated cellular events. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, and by inhibiting the Rho-associated protein kinase, it can alter actin cytoskeleton dynamics. Given IQSEC2's involvement in actin cytoskeleton reorganization, inhibition of ROCK can indirectly affect the functional activity of IQSEC2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K). PI3K is involved in a myriad of cellular functions, including those that affect the actin cytoskeleton, which is a known area of involvement for IQSEC2. By inhibiting PI3K, Wortmannin can indirectly inhibit the functionality of IQSEC2. | ||||||